After the threat of tariffs – Novartis invests 230 billion in the USA

Pharmaceutical giant Novartis plans to invest 23 billion dollarsover the next five years to expand its production in the USA. The goal is for all medicines destined for the US market to be produced within the country.

Korbinian Löbmann leads scientific meeting on drug formulation: High activity in the field

Korbinian Löbmann has moderated New Updates in Drug Formulation & Bioavailability several times before. Now he is once again taking on the scientific meeting. Life Science Sweden reached out to him.

Large study on milk: Risky for women but not for men

The risk of ischemic heart disease (IHD) and acute myocardial infarction (MI) increased for women with milk intake levels higher than 2 glasses per day, while no such association was found in men, according to a new large Swedish study.

Sobi announces agreement with Enable Injections

Swedish biopharma Sobi has entered into an international development and distribution agreement with US drug delivery company Enable Injections.

Ny kurs ska väcka passion för statistik – ”Många får panik”

Kan man förstå och tolka kliniska studier – utan att vara bra på matte? Ja, menar Anna Törner som tillsammans med Ingrid Lönnstedt skapat en onlinekurs för att fler ska våga närma sig statistiska metoder.

Anna Törner: ”Orphan Designation – the "petite robe noire" of drug development”

It is easy to cling to various regulatory incentives, like orphan designation, and other expedited pathways, without understanding what they truly mean or whether they are indeed right (or wrong) for the current project, Anna Törner writes in a column.

Anna Törner: ”Orphan designation läkemedelsutvecklingens ’petite robe noire’”

Det är så lätt att klamra sig fast vid olika regulatoriska incitament, som orphan designation, utan att egentligen veta vad de innebär och på vilket sätt de kan vara rätt (eller fel), skriver Anna Törner i en krönika.

Ny medicinsk chef på Vicore Pharma

Läkaren Bertil Lindmark blir ny medicinsk chef, Chief Medical Officer, för Vicore Pharma.

Anna Törner: ”Wegovy kommer få användning långt utöver de rent medicinska indikationerna”

Wegovy är avsedd för rejält överviktiga, men förskrivningen kommer knappast att begränsas till dem som har en svårt medicinskt belastande övervikt, skriver Anna Törner i en krönika.

Study names with an attitude – more important than you might think

Ironman, T-rex, Star-Trek. Popcorn, Proper, Scout. Nope, these are neither fantasy films nor dog names. They’re the names of ongoing cancer studies in Sweden.

The first Lyme disease vaccine faces a delay

Pfizer and Valneva’s Lyme disease vaccine, which could be the first of its kind, is facing delays of about a year. The reason is problems at trial sites in the United States, which have forced the companies to drop half of the participants in an ongoing Phase III study.

AI baserad på språkalgoritm skapade nya fungerande proteiner

Inte ens proteiner går säkra för språkrobotarna. I det senaste numret av Nature Biotechnology presenterades språkmodellen Progen som, enligt forskarna bakom studien, lärt sig semantiken och grammatiken i proteinernas språk.

A growing industry in Denmark: “One new life science company a week”

The life science sector in eastern Denmark continues to grow in the number of employees, as well as the number of companies. An emerging problem is the shortage of labour, a new report reveals.

Noxious parasite forms hybrids and deceives the immune system

The small parasite Trypanosoma cruzi has a nasty ability to cause serious illness. Researchers at the Karolinska Institutet have now mapped its ability to deceive the immune system by forming new variants that are mixtures of different strains.

Investments worth 40 billion in the Öresund region – “A huge investment wave”

A new report reveals that medical companies in the Oresund region are investing like never before.

Elicera develops CAR-T against solid tumours – may become the first in the world

Today, there are five EU-approved CAR-T therapies, all focused on different types of blood cancer, but no one has yet succeeded in making the method work against solid tumours. At Gothenburg-based Elicera, they are working relentlessly to succeed in that field as well. “It is the largest field, and the potential is enormous,” says the company’s CEO Jamal El-Mosleh.

Björn Arvidsson: ”We need to change perspective”

If you say “life science” to a person on the street and ask them to explain what it is, you will probably get no good answer. The same question to your network will generate as many versions as the people you ask. Most likely, we will miss many

Sweden and Denmark – this is how they choose their strategies

Scandinavia’s two major powers in pharmaceutical research have developed strategies for growth in life science, and both countries aim to become world leaders.

Karolinska i Europatopp när "smartaste" sjukhusen rankas

Karolinska universitetssjukhuset i Solna är bäst i Europa på att använda ny teknik inom sjukvården, enligt en rankning i tidskriften Newsweek.

Norway finds its path in life science

The life science sector in Norway is on the rise.

Olinks plattform ska användas i stort brittiskt analysprojekt

Genom att analysera proteinplasma från 53 000 britter hoppas de tio deltagande biofarmabolagen utveckla bättre läkemedel.

Krönika: Collaboration across borders

Femte förslaget till regeringen från SwedenBio

Skärp målsättningen för deltagandet i EU:s ramprogram. Det är SwedenBios femte förslag inför den kommande forskningspropositionen.

Läkemedlet som fördröjer diabetesdebut

Ett läkemedel som riktar sig mot immunsystemet har visat sig kunna fördröja insjuknandet i typ 1-diabetes. ”Ett steg närmare vårt ultimata mål: en framtid utan typ 1-diabetes.”